Bio-Rad Laboratories Inc
$ 337.00
0.00%
14 Aug - close price
- Market Cap 9,010,766,000 USD
- Current Price $ 337.00
- High / Low $ 337.00 / 337.00
- Stock P/E 41.00
- Book Value 268.30
- EPS 8.22
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE 0.03 %
- 52 Week High 337.00
- 52 Week Low 244.54
About
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets.
Analyst Target Price
N/A
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-04 | 2026-04-30 | 2026-02-12 | 2025-10-28 | 2025-07-30 | 2025-05-05 | 2025-02-13 | 2024-10-30 | 2024-08-01 | 2024-05-07 | 2024-02-29 | 2023-10-27 |
| Reported EPS | 13.851 | -19.5526 | 26.6548 | -12.6992 | 11.6718 | 2.2894 | -25.567 | 23.3401 | -76.2629 | 13.4533 | 3.1 | 2.33 |
| Estimated EPS | None | None | None | None | None | None | None | None | None | 2.99 | 2.84 | 2.76 |
| Surprise | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.4633 | 0.26 | -0.43 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | None% | None% | None% | 349.9431% | 9.1549% | -15.5797% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BIO-B
2026-08-07 02:41:30
The California State Teachers Retirement System increased its stake in Bio-Rad Laboratories (NYSE:BIO) by 22.9% in the first quarter, now owning 21,932 shares worth $6.1 million. Bio-Rad Laboratories recently reported strong Q2 adjusted earnings of $2.62 per share, exceeding analyst estimates, although revenue was flat year-over-year. Analyst sentiment for BIO is mixed, with an average "Reduce" rating and a target price of $343.33, alongside plans for job cuts and facility closures.
2026-08-06 12:09:33
Bio-Rad Laboratories' stock saw a 4.5% jump following its Q2 2026 earnings report, with revenue of US$651 million and non-GAAP EPS of US$2.62, broadly flat year-over-year. The company's digital PCR (ddPCR) revenue grew 6% with instrument sales up over 20%, supporting a "bull case" for growth through new platforms and operational tightening. However, flat currency-neutral revenue guidance and concerns about earnings volatility due to pricing pressure and weak funding remain for the "bear case."
2026-08-05 12:09:33
Bio-Rad reported a modest sequential improvement in its second-quarter earnings, with a 1.9% year-on-year revenue decline at constant currency and a non-GAAP operating margin of 12.5%. Despite this, management reiterated broad full-year guidance ranges for revenue change and operating margin, indicating continued uncertainty.
2026-07-28 19:06:35
Eva Anette Engelhardt, EVP and President, CDG of Bio-Rad Laboratories (NYSE: BIO), had 246 Restricted Stock Units vest on July 25, 2026. To cover tax obligations, 89 shares were withheld at a price of $314.46 per share. After this transaction, she holds 492 remaining RSUs, which vest at a rate of 25% annually over four years.
2026-06-25 21:20:00
Bio-Rad Laboratories (BIO) saw its stock rise 6.5% due to a major M&A deal in the life sciences tools sector and ongoing investor interest stemming from Elliott Investment Management's recent stake. The acquisition of Bio-Techne by Merck KGaA for $11.3 billion boosted valuations across comparable names, making Bio-Rad a beneficiary. This movement is attributed to sector-wide sentiment rather than a new company-specific announcement, also supported by analyst price targets and significant institutional trading activity.
2026-06-25 19:10:50
This article provides a forecast for Bio-Rad Laboratories, Inc. Class A (BUWA) stock, including price targets from analysts and historical performance. It details the company's financials, earnings reports, revenue, net income, and current market capitalization. The article also addresses frequently asked questions about BUWA's stock price, volatility, dividends, and investment recommendations.
